🧪
hypothesis

HBOT (2.0 ATA, 60 min) activates TFEB-mediated autophagy-lysosome pathway to accelerate Aβ and p-tau clearance

Hypothesis

HBOT (2.0 ATA, 60 min) activates TFEB-mediated autophagy-lysosome pathway to accelerate Aβ and p-tau clearance

HBOT increases mTORC1 inhibition, promoting TFEB nuclear translocation and enhancing autophagy flux to clear pathological proteins.
🧬 TFEB (TFE2)🩺 neurodegeneration🎯 Composite 56%💱 $0.54▼5.2%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 3 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.55 (15%) Evidence 0.58 (15%) Novelty 0.60 (12%) Feasibility 0.55 (12%) Impact 0.70 (12%) Druggability 0.52 (10%) Safety 0.60 (8%) Competition 0.55 (6%) Data Avail. 0.50 (5%) Reproducible 0.48 (5%) KG Connect 0.50 (8%) 0.560 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite56%

🧪 Overview

HBOT increases mTORC1 inhibition, promoting TFEB nuclear translocation and enhancing autophagy flux to clear pathological proteins. However, autophagy markers are easily misinterpreted (increased LC3-II can mean blocked flux), and the direction of autophagy regulation by oxygen is context-dependent. Rigorous flux validation with insoluble Aβ/tau clearance endpoints is required.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["mTORC1 Hyperactivation<br/>Nutrient/Growth Signals"]
    B["TFEB Phosphorylation<br/>Ser211 by mTORC1"]
    C["14-3-3 Sequestration<br/>Cytoplasmic Retention"]
    D["Lysosomal Biogenesis<br/>Blocked"]
    E["Autophagic Flux<br/>Impaired"]
    F["Tau/Amyloid Aggregate<br/>Accumulation"]
    G["TFEB Activation<br/>Rapamycin or MCOLN1"]
    H["Nuclear TFEB<br/>CLEAR Gene Expression"]
    G --> H
    H -.->|"rescues"| D
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style H fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix3 supports2 contradicts
Supports
TFEB overexpression reduces Aβ and tau pathology
PMID:31167123
Supports
mTOR inhibition improves cognitive function in AD models
PMID:29327743
Supports
HBOT enhanced autophagic flux in hypoxic neuronal cultures
PMID:28327691
Contradicts
Increased LC3-II can mean blocked flux, not enhanced clearance
PMID:N/A
Contradicts
Lysosomal dysfunction in AD is distal to TFEB alone
PMID:N/A
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — TFEB

No curated PDB or AlphaFold mapping for TFEB yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TFEB (TFE2) from GTEx v10.

Spinal cord cervical c-127.0 Cerebellum11.3median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TFEB (TFE2) →

No DepMap CRISPR Chronos data found for TFEB (TFE2).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.2%
Volatility
Low
0.0048
Events (7d)
2
Price History
▼5.2%

💾 Resource Usage

LLM Tokens
11,804
$0.0354
Total Cost
$0.0354

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF APP/PS1 transgenic mice receive HBOT (2.0 ATA, 60 min per session, 5 sessions/week for 4 weeks), THEN cortical insoluble Aβ42 levels will decrease by ≥30% compared to sham-treated littermate contro≥30% reduction in cortical insoluble Aβ42; TFEB nuclear localization increase ≥1.8-fold in cortical neurons; LC3-II/p62 ratio increased ≥1.5-fold indicating enh— no observation —pending0.62
IF SH-SY5Y neuroblastoma cells with doxycycline-inducible TFEB overexpression are subjected to HBOT (2.0 ATA, 60 min) in a hyperbaric chamber, THEN lysosomal protease activity (Cathepsin D) will increCathepsin D activity ≥2-fold; BODIPY-casein cleavage rate ≥40% increase; TFEB nuclear/cytosol ratio ≥2.5-fold; p62 half-life decreased by ≥50% indicating active— no observation —pending0.58
🔮 Falsifiable Predictions (2)
pendingconf 62%
IF APP/PS1 transgenic mice receive HBOT (2.0 ATA, 60 min per session, 5 sessions/week for 4 weeks), THEN cortical insoluble Aβ42 levels will decrease by ≥30% compared to sham-treated littermate controls within 2 weeks after the final session, because TFEB nuclear translocation drives autophagy-media
Predicted outcome: ≥30% reduction in cortical insoluble Aβ42; TFEB nuclear localization increase ≥1.8-fold in cortical neurons; LC3-II/p62 ratio increased ≥1.5-fold indi
Falsification: Insoluble Aβ42 unchanged or increased; TFEB remains cytosolic; LC3-II increases but p62 also accumulates (blocked flux pattern); any one failure disproves the mechanism
pendingconf 58%
IF SH-SY5Y neuroblastoma cells with doxycycline-inducible TFEB overexpression are subjected to HBOT (2.0 ATA, 60 min) in a hyperbaric chamber, THEN lysosomal protease activity (Cathepsin D) will increase ≥2-fold and long-lived protein degradation rate will increase ≥40% within 24 hours post-treatmen
Predicted outcome: Cathepsin D activity ≥2-fold; BODIPY-casein cleavage rate ≥40% increase; TFEB nuclear/cytosol ratio ≥2.5-fold; p62 half-life decreased by ≥50% indicat
Falsification: Cathepsin D activity unchanged; protein degradation rate unchanged or decreased despite LC3-II increase; p62 stable or increased (indicating flux blockade); any one failure disproves the mechanism
View on SciDEX ↗